Variation in the use of biologics in the management of rheumatoid arthritis across the UK

Current Medical Research and Opinion

Volumn 28, Issue 10, 2012, Pages 1733-1741

  Choy, Ernest ^a   Taylor, Peter ^b   McAuliffe, Sandra ^c   Roberts, Kirsty ^d   Sargeant, Ify ^e  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c McAuliffe Interim Options Ltd   (United Kingdom)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e Ismedica Ltd   (United Kingdom)

Author keywords

Biologics; Rheumatoid arthritis; Treatment patterns; Variation

Indexed keywords

ABATACEPT; ADALIMUMAB; AUROTHIOMALATE; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADOLESCENT; ADULT; AGED; COHORT ANALYSIS; DISEASE ACTIVITY; GENERAL HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; TEACHING HOSPITAL; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84867878211     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.731388     Document Type: Review

References (32)

1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800 (Pubitemid 34822963)
2. Barrett EM, Scott DG, Wiles NJ, et al. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community based study. Rheumatology (Oxford) 2000;39:1403-9 (Pubitemid 32045868)
3. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-40 (Pubitemid 34257745)
4. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006; 12:555-69 (Pubitemid 47400571)
5. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74 (Pubitemid 36004312)
6. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706 (Pubitemid 32322246)
7. Moots R, Taggart A, Walker D. Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology (Oxford) 2003;42:614-16 (Pubitemid 37220868)
8. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16, 752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85 (Pubitemid 351898370)
9. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011;17(9 Suppl B):S14-18
10. Kay LJ, Griffiths ID; BSR Biologics Register Management committee. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. Rheumatology (Oxford) 2006;45:1376-9 (Pubitemid 44605472)
11. TA130. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis-TA130. Available at: http://guidance.nice.org.uk/TA130 [Last accessed 2 July 2012]
12. Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94 (Pubitemid 43877928)
13. TA186. Certolizumab pegol for the treatment of rheumatoid arthritis-TA186. Available at: http://guidance.nice.org.uk/TA186 [Last accessed 2 July 2012]
14. TA195. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor-TA195. Available at: http://guidance.nice.org.uk/TA195 [Last accessed 2 July 2012]
15. TA198. Tocilizumab for rheumatoid arthritis-TA198. Available at: http://guidance.nice.org.uk/TA198 [Last accessed 2 July 2012]
16. EFPIA: Access to Innovative Treatments in Rheumatoid Arthritis in Europe, October 2009. A Report Prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). Available at: http://www. lif.se/default.aspx? id44400 [Last accessed 2 July 2012]
17. Miltenburger C, Gü nther OH, Justo N, et al. A Survey of Barriers to Treatment Access in Rheumatoid Arthritis in France, Germany, Italy, Spain and the UK, October 2009. Available at: http://www.comparatorreports.se/cr02a- products.htm [Last accessed 2 July 2012]
18. Arthritis Research Campaign (2002) Arthritis: The Big Picture. Chesterfield: Arthritis Research Campaign. Available at: http://www.ipsos-mori. com/Assets/Docs/Archive/Polls/arthritis.pdf [Last accessed 2 July 2012]
19. Kiely P, Walsh D, Williams R, Young A; Early Rheumatoid Arthritis Network. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology (Oxford) 2011;50:926-31
20. Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611-15
21. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9
22. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44 (Pubitemid 47492478)
23. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66
24. Penn H. Biologic therapies in autoimmune diseases. Clin Med 2006;6:105-8
25. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther 2009;11:205
26. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011;13(Suppl 1):S3
27. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094-9
28. Contreras-Yá ñ ez I, Ponce De Leó n S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010;340:282-90
29. de Klerk E, van der Heijde D, Landewé R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54 (Pubitemid 36077771)
30. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4: CD007848
31. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011;31:39-51
32. Deighton C. If it works why can't we have it? Sequential anti-TNF therapy in the UK. Why sequential anti-TNF use remains restricted in the UK. Rheumatology 2010;49:2235-6